Abnormal Activity of the MAPK- and cAMP-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem Brain in Schizophrenia

Recent evidence suggests that schizophrenia may result from alterations of integration of signaling mediated by multiple neurotransmitter systems. Abnormalities of associated intracellular signaling pathways may contribute to the pathophysiology of schizophrenia. Proteins and phospho-proteins comprising mitogen activated protein kinase (MAPK) and 3′–5′-cyclic adenosine monophosphate (cAMP)-associated signaling pathways may be abnormally expressed in the anterior cingulate (ACC) and dorsolateral prefrontal cortex (DLPFC) in schizophrenia. Using western blot analysis we examined proteins of the MAPK- and cAMP-associated pathways in these two brain regions. Postmortem samples were used from a well-characterized collection of elderly patients with schizophrenia (ACC=36, DLPFC=35) and a comparison (ACC=33, DLPFC=31) group. Near-infrared intensity of IR-dye labeled secondary antisera bound to targeted proteins of the MAPK- and cAMP-associated signaling pathways was measured using LiCor Odyssey imaging system. We found decreased expression of Rap2, JNK1, JNK2, PSD-95, and decreased phosphorylation of JNK1/2 at T183/Y185 and PSD-95 at S295 in the ACC in schizophrenia. In the DLPFC, we found increased expression of Rack1, Fyn, Cdk5, and increased phosphorylation of PSD-95 at S295 and NR2B at Y1336. MAPK- and cAMP-associated molecules constitute ubiquitous intracellular signaling pathways that integrate extracellular stimuli, modify receptor expression and function, and regulate cell survival and neuroplasticity. These data suggest abnormal activity of the MAPK- and cAMP-associated pathways in frontal cortical areas in schizophrenia. These alterations may underlie the hypothesized hypoglutamatergic function in this illness. Together with previous findings, these data suggest that abnormalities of intracellular signaling pathways may contribute to the pathophysiology of schizophrenia.

[1]  H. Corrêa,et al.  The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  Brian O. Smith,et al.  EPAC proteins transduce diverse cellular actions of cAMP , 2009, British journal of pharmacology.

[3]  J. Crandall,et al.  Cdk5 Regulates the Phosphorylation of Tyrosine 1472 NR2B and the Surface Expression of NMDA Receptors , 2008, The Journal of Neuroscience.

[4]  V. Haroutunian,et al.  Evidence for Abnormal Forward Trafficking of AMPA Receptors in Frontal Cortex of Elderly Patients with Schizophrenia , 2010, Neuropsychopharmacology.

[5]  D. Surmeier,et al.  Kalirin-7 Controls Activity-Dependent Structural and Functional Plasticity of Dendritic Spines , 2007, Neuron.

[6]  Eric Klann,et al.  Activation of exchange protein activated by cyclic-AMP enhances long-lasting synaptic potentiation in the hippocampus. , 2008, Learning & memory.

[7]  V. Pawlak,et al.  Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors , 2007, Neuropharmacology.

[8]  K. Fukunaga,et al.  Enhanced activation of Ca2+/Calmodulin‐dependent protein kinase II upon downregulation of cyclin‐dependent kinase 5‐p35 , 2006, Journal of neuroscience research.

[9]  T. Asada,et al.  Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  Philip D. Harvey,et al.  The Course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous History of Long-Term Institutional Stay , 2010, Biological Psychiatry.

[11]  J. Sweatt,et al.  The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory , 2001, Journal of neurochemistry.

[12]  M. Luca,et al.  Dual role of CaMKII‐dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A , 2007, Journal of neurochemistry.

[13]  Guang-yi Zhang,et al.  PSD-95 promotes CaMKII-catalyzed serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP after transient brain ischemia in rat hippocampus , 2004, Brain Research.

[14]  J. Meador-Woodruff,et al.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia , 2008, Schizophrenia Research.

[15]  R. Huganir,et al.  Rapid and bi-directional regulation of AMPA receptor phosphorylation and trafficking by JNK , 2008, The EMBO journal.

[16]  V. Haroutunian,et al.  Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.

[17]  A. Reichenberg,et al.  The assessment of neuropsychological functioning in schizophrenia , 2010, Dialogues in clinical neuroscience.

[18]  B. Burke,et al.  Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder , 2011, Neuropathology and applied neurobiology.

[19]  Y. Ip,et al.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.

[20]  R. Huganir,et al.  Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs , 2000, The Journal of Neuroscience.

[21]  V. Haroutunian,et al.  Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia , 2006, Molecular Psychiatry.

[22]  R. Murray,et al.  PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .

[23]  J. Meador-Woodruff,et al.  Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder , 2001, Brain Research Bulletin.

[24]  K. Tang,et al.  Spatial and Temporal Regulation of RACK1 Function and N-methyl-D-aspartate Receptor Activity through WD40 Motif-mediated Dimerization* , 2004, Journal of Biological Chemistry.

[25]  J. Sweatt,et al.  Mitogen-activated protein kinases in synaptic plasticity and memory , 2004, Current Opinion in Neurobiology.

[26]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[27]  K. Davies,et al.  Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices , 2009, Neuroscience.

[28]  N. Ip,et al.  Integration of Signals from Receptor Tyrosine Kinases and G Protein-Coupled Receptors , 2002, Neurosignals.

[29]  D. Purpura,et al.  NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders , 2007, Nature Reviews Neuroscience.

[30]  L. Tsai,et al.  Reelin and Cyclin-Dependent Kinase 5-Dependent Signals Cooperate in Regulating Neuronal Migration and Synaptic Transmission , 2004, The Journal of Neuroscience.

[31]  Y. Ben-Ari,et al.  Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal‐regulated kinases (ERK) activity in cultured rat hippocampal neurons , 2006, The Journal of physiology.

[32]  A. Elbein,et al.  Increased Expression of c-Jun Transcription Factor in Cerebellar Vermis of Patients with Schizophrenia , 2003, Neuropsychopharmacology.

[33]  G. Winterer,et al.  The Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia , 2008, Pharmacopsychiatry.

[34]  Angus W MacDonald,et al.  What we know: findings that every theory of schizophrenia should explain. , 2009, Schizophrenia bulletin.

[35]  D. Hochbaum,et al.  Epac, in Synergy with cAMP-dependent Protein Kinase (PKA), Is Required for cAMP-mediated Mitogenesis* , 2008, Journal of Biological Chemistry.

[36]  R. Huganir,et al.  Characterization of Protein Kinase A and Protein Kinase C Phosphorylation of the N-Methyl-D-aspartate Receptor NR1 Subunit Using Phosphorylation Site-specific Antibodies* , 1997, The Journal of Biological Chemistry.

[37]  A. Bonci,et al.  NMDA receptor function is regulated by the inhibitory scaffolding protein, RACK1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  V. Haroutunian,et al.  Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia , 2008, Biological Psychiatry.

[39]  J.F.W. Deakin,et al.  Neurobiology of schizophrenia , 1996 .

[40]  L. Tsai,et al.  Cyclin-Dependent Kinase 5 Phosphorylates the N-Terminal Domain of the Postsynaptic Density Protein PSD-95 in Neurons , 2004, The Journal of Neuroscience.

[41]  Angus C Nairn,et al.  DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.

[42]  M. Sheng,et al.  Synaptic Accumulation of PSD-95 and Synaptic Function Regulated by Phosphorylation of Serine-295 of PSD-95 , 2007, Neuron.

[43]  V. Haroutunian,et al.  Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia , 2010, Schizophrenia Research.

[44]  M. di Luca,et al.  Calcium–calmodulin‐dependent protein kinase II phosphorylation modulates PSD‐95 binding to NMDA receptors , 2006, The European journal of neuroscience.

[45]  R. Davis,et al.  Signal transduction by the c-Jun N-terminal kinase. , 1999, Biochemical Society symposium.

[46]  M. Laruelle,et al.  Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. , 2003, Annals of the New York Academy of Sciences.

[47]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[48]  R. Duncan,et al.  Specific Targeting of Pro-Death NMDA Receptor Signals with Differing Reliance on the NR2B PDZ Ligand , 2008, The Journal of Neuroscience.

[49]  J. Zhu,et al.  Rap2-JNK Removes Synaptic AMPA Receptors during Depotentiation , 2005, Neuron.

[50]  V. Haroutunian,et al.  Expression of the NR2B‐NMDA receptor subunit and its Tbr‐1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia , 2010, Synapse.

[51]  P. Dutar,et al.  The magnitude of hippocampal long term depression depends on the synaptic location of activated NR2-containing N-methyl-d-aspartate receptors , 2008, Neuroscience.

[52]  J. Meador-Woodruff,et al.  NMDA receptors and schizophrenia. , 2007, Current opinion in pharmacology.

[53]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[54]  Jürgen Gallinat,et al.  Molecular Mechanisms of Schizophrenia , 2007, Cellular Physiology and Biochemistry.

[55]  V. Haroutunian,et al.  Expression of four housekeeping proteins in elderly patients with schizophrenia , 2009, Journal of Neural Transmission.

[56]  Chia-Hsiang Chen,et al.  Genetic and Functional Analysis of the DLG4 Gene Encoding the Post-Synaptic Density Protein 95 in Schizophrenia , 2010, PloS one.

[57]  D. Choquet,et al.  Surface trafficking of N-methyl-d-aspartate receptors: Physiological and pathological perspectives , 2009, Neuroscience.

[58]  P. Greengard,et al.  Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation , 2007, Nature Neuroscience.

[59]  D. Volk,et al.  Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. , 2010, The American journal of psychiatry.

[60]  Xiaodong Cheng,et al.  Epac and PKA: a tale of two intracellular cAMP receptors. , 2008, Acta biochimica et biophysica Sinica.

[61]  J. Kennedy,et al.  Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia , 2008, Schizophrenia Research.

[62]  C. Karson,et al.  Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients. , 2000, Archives of General Psychiatry.

[63]  TylerZARUBIN,et al.  Activation and signaling of the p38 MAP kinase pathway , 2005 .

[64]  M. Karayiorgou,et al.  Decreased Phosphorylation of NMDA Receptor Type 1 at Serine 897 in Brains of Patients with Schizophrenia , 2004, The Journal of Neuroscience.

[65]  K. Dalby,et al.  Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation , 2008, Journal of Pharmacology and Experimental Therapeutics.

[66]  G. Rumbaugh,et al.  Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia , 2009, Neuroreport.

[67]  S. Arnold,et al.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs , 2007, Schizophrenia Research.

[68]  David G Standaert,et al.  Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. , 2004, Molecular pharmacology.

[69]  S. Kyosseva Mitogen-activated protein kinase signaling. , 2004, International review of neurobiology.

[70]  R. Huganir,et al.  MINK and TNIK Differentially Act on Rap2-Mediated Signal Transduction to Regulate Neuronal Structure and AMPA Receptor Function , 2010, The Journal of Neuroscience.

[71]  M. Karin,et al.  c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases , 1994, Molecular and cellular biology.

[72]  H. Manji,et al.  Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. , 2010, Journal of affective disorders.

[73]  P. Greengard,et al.  Diverse Psychotomimetics Act Through a Common Signaling Pathway , 2003, Science.

[74]  David M. Santucci,et al.  The Effects of NR2 Subunit-Dependent NMDA Receptor Kinetics on Synaptic Transmission and CaMKII Activation , 2008, PLoS Comput. Biol..

[75]  H. Bading,et al.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.

[76]  E. Choi,et al.  Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.

[77]  J. Kleinman,et al.  Psychiatric Brain Banking: Three Perspectives on Current Trends and Future Directions , 2011, Biological Psychiatry.

[78]  J. Meador-Woodruff,et al.  Glutamate receptor expression in schizophrenic brain , 2000, Brain Research Reviews.

[79]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[80]  V. Haroutunian,et al.  mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics , 2005, Journal of neuroscience research.

[81]  J. Kennedy,et al.  Genetics in schizophrenia: where are we and what next? , 2010, Dialogues in clinical neuroscience.

[82]  F. Fumagalli,et al.  Antipsychotic drug actions on gene modulation and signaling mechanisms. , 2009, Pharmacology & therapeutics.

[83]  Philip D. Harvey,et al.  Assessment of dementia in elderly schizophrenics with structured rating scales , 1992, Schizophrenia Research.

[84]  T. Palmer,et al.  Regulating gene transcription in response to cyclic AMP elevation. , 2008, Cellular signalling.

[85]  H. Chi,et al.  Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. , 2009, Cytokine.

[86]  H. Wright,et al.  Phencyclidine-induced psychosis. , 1980, Southern medical journal.

[87]  Vahram Haroutunian,et al.  Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study , 2005, Schizophrenia Research.

[88]  K. Mikoshiba,et al.  Modulation of Reelin signaling by Cyclin-dependent kinase 5 , 2007, Brain Research.

[89]  Svetlana V. Kyosseva,et al.  Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[90]  M. Bogoyevitch,et al.  c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. , 2010, Biochimica et biophysica acta.

[91]  V. Haroutunian,et al.  Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex , 2006, Synapse.

[92]  M. Lyon,et al.  Mitogen-activated protein kinases in schizophrenia , 1999, Biological Psychiatry.

[93]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[94]  K. Davis,et al.  Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. , 2005, The American journal of psychiatry.

[95]  M. Ahmadian,et al.  The C2 domain of SynGAP is essential for stimulation of the Rap GTPase reaction , 2008, EMBO reports.

[96]  P. Calabresi,et al.  Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression , 2009, The Journal of Neuroscience.

[97]  T. Hashimoto,et al.  Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. , 2007, International review of neurobiology.

[98]  J. Sweatt,et al.  The Mitogen-Activated Protein Kinase Cascade Couples PKA and PKC to cAMP Response Element Binding Protein Phosphorylation in Area CA1 of Hippocampus , 1999, The Journal of Neuroscience.

[99]  K. Davis,et al.  Postmortem studies in schizophrenia , 2000, Schizophrenia bulletin.

[100]  M. Laruelle,et al.  Glutamate, Dopamine, and Schizophrenia , 2003 .

[101]  Karen Faith Berman,et al.  Executive Function, Neural Circuitry, and Genetic Mechanisms in Schizophrenia , 2010, Neuropsychopharmacology.

[102]  R. Siegel,et al.  Association of PSD‐95 with ErbB4 facilitates neuregulin signaling in cerebellar granule neurons in culture , 2007, Journal of neurochemistry.

[103]  T. Abel,et al.  Exchange protein activated by cAMP enhances long-term memory formation independent of protein kinase A. , 2009, Learning & memory.

[104]  Philip D. Harvey,et al.  Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. , 1995, The American journal of psychiatry.

[105]  H. Bading,et al.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.

[106]  R. Anwyl,et al.  Extrasynaptic NR2D-Containing NMDARs Are Recruited to the Synapse during LTP of NMDAR-EPSCs , 2008, The Journal of Neuroscience.

[107]  Kari Stefansson,et al.  Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/− Knock-Outs Compared with Wild-Type Mice , 2007, The Journal of Neuroscience.

[108]  Paul Greengard,et al.  Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. , 2002, Archives of general psychiatry.

[109]  D. Clapham,et al.  SynGAP-MUPP1-CaMKII Synaptic Complexes Regulate p38 MAP Kinase Activity and NMDA Receptor- Dependent Synaptic AMPA Receptor Potentiation , 2004, Neuron.

[110]  S. Akbarian,et al.  Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders , 2006, Brain Research Reviews.

[111]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[112]  Georg Winterer,et al.  Why do patients with schizophrenia smoke? , 2010, Current opinion in psychiatry.

[113]  S. Fatemi,et al.  The neurodevelopmental hypothesis of schizophrenia, revisited. , 2009, Schizophrenia bulletin.